High-dose chemotherapy with autologous stem cell transplantation has become standard of care for patients with relapsed aggressive non-Hodgkin’s lymphoma (NHL).
High-dose busulfan, cyclophosphamide and etoposide is an effective regimen resulting in long-term disease-free survival in relapsed malignant lymphoma and prior radiation therapy. The toxicity is moderate with a low treatment-related mortality.
NHL patients include diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and peripheral T-cell lymphoma.